DRUG

#2302
Bright Minds Biosciences Inc. - common stock
88.0 7 USD
-1.82%
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
88.07
88.07
Year Range
23.18
123.75
Daily Change
-1.82%
Monthly Change
-1.01%
6 month change
+26.27%
Year Change
+224.98%
Previous Close
89.7 0
Open
88.0 7
Low
88.0 7
High
88.0 7
Volume
24
Open full chart Full chart

Financials

Overview Statement Statistics
Quarterly Annual
Income statement Balance sheet Cash flow
Value 20212022202320242025 TTM

Bright Minds Biosciences Inc. - common stock

Bright Minds Biosciences is an American pharmaceutical company which is developing serotonin 5-HT₂ receptor agonists for potential medical use. It has a particular focus on serotonin 5-HT2C receptor agonists, for instance to treat rare epilepsies and other conditions. Another area of focus for the company is serotonergic psychedelics and non-hallucinogenic psychoplastogens. The company was co-founded by Ian McDonald and Gideon Shapiro. The lead scientist at Bright Minds Biosciences was previously Alan Kozikowski. Bright Mind Biosciences was founded in 2017 and its headquarters are in New York City, New York.

News